Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is set to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.58) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company had revenue of $77.97 million for the quarter, compared to analysts’ expectations of $60.15 million. During the same quarter in the previous year, the company posted ($2.47) earnings per share. The business’s revenue for the quarter was up 2621.5% compared to the same quarter last year. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Sage Therapeutics Price Performance
Shares of NASDAQ:SAGE opened at $12.95 on Wednesday. Sage Therapeutics has a 12 month low of $10.92 and a 12 month high of $59.99. The stock has a market cap of $778.42 million, a price-to-earnings ratio of -1.43 and a beta of 0.86. The stock’s 50 day moving average price is $19.22 and its 200 day moving average price is $20.78.
Analysts Set New Price Targets
Check Out Our Latest Report on Sage Therapeutics
Sage Therapeutics Company Profile
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Recommended Stories
- Five stocks we like better than Sage Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- Charles Schwab Fortifies its Uptrend on EPS Beat
- How to Choose Top Rated Stocks
- Lockheed Martin Stock Aims for a Fresh All-Time High
- How to Calculate Inflation Rate
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.